NanoCelle Sermorelin (NC-SER)
Imagine, a drug that effectively reduces fat, increases libido and muscle mass.
This is anti-aging!
Headline numbers
~51% of U.S. adults (≈130 million) had ≥2 chronic conditions in 2023 (BRFSS). This is the clearest population indicator of disease-linked accelerated aging. CDC
~10–16% of community-dwelling U.S. adults ≥65 are frail (with ~40–45% prefrail). Frailty = clinically evident accelerated physiological aging. SAGE JournalsUpToDate
~5% of adults show very large epigenetic age acceleration (>10 years); a larger share (≈15–30%) show moderate positive acceleration depending on the clock and threshold used. EAA is concentrated in people with chronic disease, low SES, obesity, smoking and other risk exposures. National Institute on Aging SpringerLink
Sermorelin is a growth hormone administered by injection. Known for complicated manufacturing and stability issues, this once FDA approved drug was withdrawn from the market due to the aforementioned issues and not safety or efficacy. Medlab sees promise in developing Sermorelin with NanoCelle and offering administration as either a nasal or buccal spray.
Medlab believes a stable, patient convenient, non invasive NanoCelle Seromelin spray has significant market opportunities in the anti-aging segment, considering the vast population exposed to accelerated aging due to disease or environment.
PROGRESSION STATUS
Principle Agency: FDA
Proposed Pathway: 505(b)(2)
Initial Indication: Muscular Hypertrophy and Weight Loss
Claim Expansion: Unsure
Next: pre-clinical commencement
Next Trial: n/a
EA-IND : Applications closed at this time
Physician Led IND: Applications closed at this time